

FIG. 1
PXRD Pattern of Form A




FIG. 2
DSC Thermogram of Form A




FIG. 3
TGA Thermogram of Form A




FIG. 4

Moisture sorption isotherms of Form A




FIG. 5

SAD - Healthy Subjects





FIG. 6
MAD – Healthy Subjects








FIG. 8**Rate of Change in ppFVC**

*All observed data regardless of dose reduction were included and analyzed as randomized; †All observed data prior to dose reduction were included and analyzed as randomized. Thus, data on and after dose reduction were excluded; ‡Linear mixed model (IPF): ppFVC (%) = treatment + time + treatment*time + antifibrotic drug type + region. §Linear mixed model (PPF): ppFVC (%) = treatment + time + treatment*time + exposure to antifibrotics + UIP pattern. The difference in rate of change in ppFVC for each Compound A arm compared with placebo is shown (along with corresponding 95% CIs) in each graph. CI, confidence interval; IPF, idiopathic pulmonary fibrosis; PPF, progressive pulmonary fibrosis; ppFVC, percent of predicted forced vital capacity; SE, standard error; UIP, usual interstitial pneumonia.


9/18

FIG. 9
Change in FVC (mL)




*All observed data regardless of dose reduction were included and analyzed as randomized; †All observed data prior to dose reduction were included and analyzed as randomized. Thus, data on and after dose reduction were excluded; ‡Linear mixed model (IPF): FVC (mL) = treatment + time + treatment*time + antifibrotic drug type + region + age + sex + height; §Linear mixed model (PPF): FVC (mL) = treatment + time + treatment*time + exposure to antifibrotics + UIP pattern + age + sex + height. CI, confidence interval; FVC, forced vital capacity; IPF, idiopathic pulmonary fibrosis; PPF, progressive pulmonary fibrosis; SE, standard error.

FIG. 10



*Included all observed data regardless of dose reduction, analyzed as randomized. [†]Mixed effect model for repeated measures (IPF): change from baseline in FVC (mL) = treatment + visit + treatment*visit + antifibrotic drug type + region + age + sex + height + baseline FVC (mL). [‡]Mixed effect model for repeated measures (PPF): change from baseline in FVC (mL) = treatment + visit + treatment*visit + exposure to antifibrotics + UIP pattern + age + sex + height + baseline FVC (mL). FVC, forced vital capacity; IPF, idiopathic pulmonary fibrosis; PPF, progressive pulmonary fibrosis; SE, standard error; UIP, usual interstitial pneumonia.

11/18

FIG. 11**Rate of Change in ppFVC According to Background Antifibrotic Use**

*All observed data regardless of dose reduction were included and analyzed as randomized; [†]Linear mixed model (IPF): ppFVC (%) = treatment + time + treatment*time + region; [‡]Linear mixed model (PPF): ppFVC (%) = treatment + time + treatment*time + UIP pattern. CI, confidence interval; IPF, idiopathic pulmonary fibrosis; PPF, progressive pulmonary fibrosis; ppFVC, percent of predicted forced vital capacity; SE, standard error; UIP, usual interstitial pneumonia.

FIG. 12

Line Plot of Mean Observed Change from Baseline – ppFVC (%)
Progressive Fibrotic Interstitial Lung Disease Cohort – (Main Study)
Full Analysis Set
Primary Estimand (Treatment Policy Strategy)




FIG. 13

Line Plot of Mean Observed Change from Baseline – FVC (mL)
Progressive Fibrotic Interstitial Lung Disease Cohort – (Main Study)
Full Analysis Set
Primary Estimand (Treatment Policy Strategy)




FIG. 14

Line Plot of Mean Observed Change from Baseline – ppFVC (%) – UIP Subgroup
Progressive Fibrotic Interstitial Lung Disease Cohort – (Main Study)
Full Analysis Set
Primary Estimand (Treatment Policy Strategy)
UIP Subgroup : Yes




FIG. 15

Line Plot of Mean Observed Change from Baseline – ppFVC (%) – UIP Subgroup
Progressive Fibrotic Interstitial Lung Disease Cohort – (Main Study)
Full Analysis Set
Primary Estimand (Treatment Policy Strategy)
UIP Subgroup : No





FIG. 16

Rate of Change in ppFVC According to UIP Pattern



*All observed data regardless of dose reduction were included and analyzed as randomized; [†]Linear mixed model: ppFVC (%) = treatment + time + treatment*time + exposure to antifibrotics. CI, confidence interval; PPF, progressive pulmonary fibrosis; ppFVC, percent of predicted forced vital capacity; SE, standard error; UIP, usual interstitial pneumonia.

FIG. 17

Line Plot of Mean Observed Change from Baseline – ppFVC (%) – Antifibrotics Subgroup
Progressive Fibrotic Interstitial Lung Disease Cohort – (Main Study)
Full Analysis Set
Primary Estimand (Treatment Policy Strategy)
Antifibrotics Subgroup : Antifibrotics




FIG. 18

Line Plot of Mean Observed Change from Baseline – ppFVC (%) – Antifibrotics Subgroup
Progressive Fibrotic Interstitial Lung Disease Cohort – (Main Study)
Full Analysis Set
Primary Estimand (Treatment Policy Strategy)
Antifibrotics Subgroup : No Antifibrotics

